#United States #Boston #Lilly #Ascidian Therapeutics #RNA Exon Editors

Ascidian and Lilly Collaborate on RNA Exon Editing for Kidney Diseases

In an exciting development in biotechnology, Ascidian Therapeutics and Eli Lilly have announced a global research collaboration aimed at advancing RNA exon editing techniques to combat hereditary kidney diseases. This partnership aims to harness the capabilities of Ascidian's innovative technology, which focuses on editing RNA at a foundational level, combined with Lilly's extensive expertise in genetic medicines.

Ascidian’s leading-edge RNA exon editing platform allows for significant alterations to be made to entire exons, the segments of DNA that encode proteins. By precisely targeting genetic mutations, this technology holds the promise of providing effective treatment options for patients suffering from various rare inherited kidney conditions. The significance of this partnership lies not only in the technology itself but also in the target diseases, which have long been considered challenging to treat.

Michael Ehlers, M.D., Ph.D., the CEO of Ascidian, underscored the urgency of treating monogenic kidney diseases, stating that patients facing these serious health challenges deserve innovative solutions. He emphasized the potential of their RNA-based approach, highlighting that the technology does not alter DNA but rewrites genetic instructions at their source, thereby providing new therapeutic avenues for diseases previously deemed untreatable.

Under the terms of their agreement, Lilly will obtain exclusive rights to utilize Ascidian's RNA exon editing technology for certain undisclosed kidney disease targets. Ascidian is set to lead the discovery process along with selected preclinical activities while Lilly will take charge of more advanced preclinical studies, alongside clinical development, manufacturing, and commercialization efforts. This collaborative effort positions both firms to make substantial strides in the field of genetic kidney diseases.

The financial implications of this collaboration are significant, with Ascidian poised to receive up to $1.9 billion. This amount includes upfront payments, milestone payments linked to development plans, and tiered royalties from future sales of the resultant treatments. Notably, Ascidian retains the rights to explore other targets in renal medicine independently or engage additional partners in their pursuits.

Kidney diseases represent a pressing concern, affecting over 3.5 million individuals in the United States alone, with more than 60 known genetic diseases impacting kidney functionality. The mutations leading to these conditions are often located in large genes or feature heterogeneous alterations that current therapies cannot address. Ascidian’s approach using natural RNA splicing mechanisms aims to merge the strengths of gene therapies with reduced risks prevalent in traditional gene editing.

About Ascidian Therapeutics: Ascidian Therapeutics is innovating the landscape of disease treatment through its groundbreaking RNA rewriting capabilities. By focusing on post-transcriptional editing, Ascidian aims to produce fully functional proteins in precise cellular contexts with the hope that patients will benefit from potentially curative one-time therapies. With a portfolio of programs that focus on retinal, renal, neurological, and neuromuscular diseases, the firm is well-positioned to make impactful changes in patient lives.

For more information about Ascidian's ongoing clinical trials and their work in the field, visit Ascidian's website or their dedicated clinical trial site. This collaboration stands as a beacon of hope for patients and families seeking breakthroughs in treatments for inherited kidney diseases.